Accordingly, the role for dietary plasma BCAA reduction as a nutritional strategy to improve metabolic health should be explored in future studies, and take into account obesity, insulin sensitivity, ethnicity, and prevailing levels of circulating BCAAs. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.